Description
Copper bis-3,5-diisopropylsalicylate exhibits anti-diabetic, analgesic, antioxidative, immunomodulatory, anti-fibrotic, and anticancer chemotherapeutic activities. Copper bis-3,5-diisopropylsalicylate decreases hyperglycemia and DNA damage in diabetic rats and also exhibits radical scavenging and electron accepting abilities in other models. This compound increases levels of bronchoalveolar cells and neutrophils, decreases levels of macrophages and lymphocytes, and suppresses the development of lung fibrosis in animal models. Additionally, copper bis-3,5-diisopropylsalicylate decreases tumor growth and increases survival rates in animal models of mammary cancer.
References
Qazzaz M, Abdul-Ghani R, Metani M, et al. The antioxidant activity of copper(II) (3,5-diisopropyl salicylate)4 and its protective effect against streptozotocin-induced diabetes mellitus in rats. Biol Trace Elem Res. 2013 Jul;154(1):88-96. PMID: 23677849.
Baquial JG, Sorenson JR. Down-regulation of NADPH-diaphorase (nitric oxide synthase) may account for the pharmacological activities of Cu(II)2 (3,5-diisopropylsalicylate)4. J Inorg Biochem. 1995 Nov 1;60(2):133-48. Erratum in: J Inorg Biochem. 1997 Nov 15;68(3):233. PMID: 8530918.
Denis M. Antioxidant therapy partially blocks immune-induced lung fibrosis. Inflammation. 1995 Apr;19(2):207-19. PMID: 7601506.
Crispens CG Jr, Sorenson JR. Activity of CuDIPS against mammary cancer in C3H HeNCR mice. Anticancer Res. 1992 Jul-Aug;12(4):1271-3. PMID: 1503420.
